UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 21.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 363,674 shares of the biotechnology company's stock after buying an additional 65,220 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.25% of Aurinia Pharmaceuticals worth $3,266,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. SBI Securities Co. Ltd. bought a new position in Aurinia Pharmaceuticals in the 4th quarter worth $25,000. Tower Research Capital LLC TRC grew its stake in shares of Aurinia Pharmaceuticals by 368.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 2,635 shares during the period. Vermillion & White Wealth Management Group LLC purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter worth approximately $31,000. Natixis bought a new stake in Aurinia Pharmaceuticals during the 4th quarter worth approximately $49,000. Finally, Blue Trust Inc. lifted its holdings in Aurinia Pharmaceuticals by 3,041.4% during the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 6,174 shares in the last quarter. 36.83% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, March 27th.

Aurinia Pharmaceuticals Price Performance

Shares of Aurinia Pharmaceuticals stock traded down $0.05 on Monday, hitting $8.14. 1,009,151 shares of the company traded hands, compared to its average volume of 1,336,532. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The stock has a market capitalization of $1.10 billion, a P/E ratio of -54.26 and a beta of 1.15. The business has a 50-day simple moving average of $7.95 and a 200 day simple moving average of $8.26. Aurinia Pharmaceuticals Inc. has a 52 week low of $5.15 and a 52 week high of $10.67.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.08. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%. The business had revenue of $62.47 million for the quarter, compared to analysts' expectations of $61.06 million. Research analysts expect that Aurinia Pharmaceuticals Inc. will post 0.11 earnings per share for the current fiscal year.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.